Background: Limitations in the Precision of Traditional Microbiome Modulation Techniques and Multi-Omics Metabolic Flux Data Bottlenecks in R&D for Refractory Diseases

Conventional fecal microbiota transplantation (FMT) and probiotic therapies have revealed fundamental limitations in performing selective elimination and precise editing at the strain level within the intestinal microenvironment. Existing static analytical standard guidelines fail to preemptively control inter-species genetic incompatibility, cell lysis-induced structural degradation noise, and antagonistic feedback fluxes. Consequently, a genomic data bottleneck persists, where therapeutic effective strains fail to stably colonize the intestinal mucosal microenvironment and maintain a minimum effective prophylactic concentration. In particular, in clinical R&D for inflammatory bowel disease (IBD) and metabolic diseases, the absence of a quantifiable baseline to interpret patient-specific microbiome genetic gradients and heterogeneity has maximized therapeutic response variability, leading to a stagnant state where it is difficult to predict the bioavailability of new drug pipelines. This has resulted in significant costs associated with demonstrating clinical efficacy.

Discovery: CRISPR-Cas Based Synthetic Bacteriophage Modality Activation and Single-Cell Resolution Multi-Omics Independent Variable Tensor Synchronization Demonstration

To address this, synthetic bacteriophages equipped with CRISPR-Cas were designed to selectively eliminate only the pathogenic factors of target strains in a simulated environment. This system modulates the free energy of target sequence binding and calculates in silico the differential equation-based ligand-receptor rate constant, physically neutralizing the source of disease without destroying non-target bacteria. Batch effects in sequencing data were removed using dimensionality reduction algorithms, and multi-dimensional independent variables at the single-cell resolution were synchronized into a tensor matrix. This revealed the topological variation curve of the downstream transcriptome network of the epithelial barrier and demonstrated that this gene editing modality maintains the molecular integrity of complex metabolic circuits while effectively controlling inflammatory cytokine pathways. This completely eliminates the critical multi-drug resistance blind spot of traditional antibiotic therapies.

Establishment of a Model for Coordinating Microbiome Genetic Gradients and Reversible Host-Microbe Homeostatic Precision Layering

This architecture constructs a precision layering model by quantifying the unique gut microbiota and metabolome signatures of patients through a multi-omics matrix. This allows for the simulation of drug responses by patient lineage and genotype, and the precise control of rate-limiting step constants in the intestinal bile acid metabolism and short-chain fatty acid (SCFA) transport pathways. By up- and down-regulating fluctuating metabolic enzyme activity in the model under stress conditions, a computational backbone is secured that can autonomously and reversibly modulate the homeostasis of the intestinal mucosal microenvironment even in the face of external perturbations. This goes beyond simple qualitative observations to reconstruct the high-resolution map of organic interactions with the host genome, enabling real-time biological control. As a result, microenvironmental variations caused by various ethnic and environmental factors can be mathematically regulated.

Prospects: Establishment of a Programmable Synthetic Biology Standard and Activation of a Next-Generation IND Digital Governance

This genome precision editing platform completely resets microbiome R&D governance from static, post-hoc analysis to a programmable architecture based on in silico prediction. By linking genetic gradient correction coefficients in the screening stage, batch effects and deviations that occur during large-scale production are minimized, maximizing the reproducibility of efficacy. This meets the companion diagnostic (CDx) standards, providing safety data through simulation when submitting an Investigational New Drug (IND) application for clinical trials of Live Biotherapeutic Product (LBP) drug candidates, shortening the approval timeline with global regulatory agencies such as the U.S. FDA. Following the approval of Celyad Oncology's SER-109, this phage- and CRISPR-based platform will establish a monopolistic computational moat in the global microbiome drug market. This will accelerate the acquisition of a unique competitive advantage in the bio-platform technology business.